255 related articles for article (PubMed ID: 24932278)
1. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.
Wang X; Yang KH; Wanyan P; Tian JH
Oncol Lett; 2014 Jun; 7(6):1997-2002. PubMed ID: 24932278
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
3. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
Brown-Glaberman U; Stopeck AT
Biologics; 2012; 6():89-99. PubMed ID: 22532777
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
5. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
7. Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
Chen F; Pu F
Oncol Res Treat; 2016; 39(7-8):453-9. PubMed ID: 27487236
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.
Steger GG; Bartsch R
Ther Adv Med Oncol; 2011 Sep; 3(5):233-43. PubMed ID: 21957430
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.
Scott LJ; Muir VJ
Drugs; 2011 May; 71(8):1059-69. PubMed ID: 21668042
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.
Clemons M; Gelmon KA; Pritchard KI; Paterson AH
Curr Oncol; 2012 Oct; 19(5):259-68. PubMed ID: 23144574
[TBL] [Abstract][Full Text] [Related]
12. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Kohno N
Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
[TBL] [Abstract][Full Text] [Related]
13. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
14. Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.
Li BT; Wong MH; Pavlakis N
J Clin Med; 2014 Jan; 3(1):1-24. PubMed ID: 26237249
[TBL] [Abstract][Full Text] [Related]
15. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
17. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
18. Management of bone metastases in refractory prostate cancer--role of denosumab.
Paller CJ; Carducci MA; Philips GK
Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis.
Chen J; Zhou L; Liu X; Wen X; Li H; Li W
Int J Clin Pharm; 2021 Feb; 43(1):2-10. PubMed ID: 32964403
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]